Craniopharyngiomas are histologically benign yet locally destructive epithelial sellar and suprasellar tumors. They frequently recur despite aggressive microsurgical resection. Due to close proximity to the optic apparatus, hypothalamus, and pituitary stalk, radical extirpation carries significant morbidity. Consequently, clinicians increasingly utilize stereotactic radiosurgery for craniopharyngioma to optimize tumor control while minimizing adjacent tissue toxicity. A definitive international multi-institutional study by the International Radiosurgery Research Foundation (IRRF) now provides crucial long-term insights into the safety and oncologic efficacy of this approach across comprehensive clinical cohorts.

The Clinical Burden and Evolution of Stereotactic Radiosurgery for Craniopharyngioma

Craniopharyngiomas account for approximately two to five percent of primary intracranial neoplasms. Although histologically benign, their aggressive anatomical behavior presents severe neurosurgical challenges. Patients frequently experience visual field defects, progressive endocrinopathies, and debilitating hypothalamic dysregulation. Historically, neurosurgeons attempted radical gross total resection to avoid recurrence. However, aggressive surgery often caused permanent hypopituitarism, central diabetes insipidus, visual loss, and hypothalamic obesity. Therefore, modern management protocols prioritize maximal safe resection combined with targeted adjuvant irradiation. Stereotactic radiosurgery delivers highly conformal radiation doses with steep dose gradients. This precision spares the sensitive optic chiasm, pituitary gland, and surrounding neurovascular networks from excessive radiation exposure. Gamma Knife and linear accelerator systems enable sub-millimeter targeting accuracy. Consequently, radiosurgery has transitioned from an experimental salvage technique to a standard upfront or adjuvant therapeutic pillar for recurrent or residual sellar masses. The IRRF multicenter analysis provides essential real-world evidence validating this paradigm shift across diverse global neurosurgical centers.

Study Design and Methodology of the IRRF Multicenter Cohort

The International Radiosurgery Research Foundation conducted a robust retrospective cohort investigation across 13 major international centers. The study evaluated 296 patients undergoing stereotactic radiosurgery for craniopharyngioma over extended observation periods. The median patient age at first radiosurgical treatment was 33.6 years. Furthermore, the median tumor volume measured 1.32 cm³, reflecting typical post-surgical residual or recurrent lesions. Radiation oncologists and neurosurgeons prescribed a median margin dose of 12.0 Gy to the tumor periphery. The primary study endpoint focused on actuarial local tumor control. Meanwhile, secondary endpoints evaluated progression-free survival, overall survival, and long-term neurofunctional preservation. Investigators utilized Kaplan-Meier survival analyses to determine long-term oncologic metrics across time points. In addition, multivariable Cox proportional hazards models identified specific clinical and radiographic predictors governing local control. This collaborative international framework provides one of the largest and most authoritative data sets evaluating stereotactic radiation for these complex sellar neoplasms.

Long-Term Local Control and Survival Metrics

The study demonstrated durable and impressive oncologic efficacy across extensive post-treatment follow-up windows. The actuarial local tumor control rates reached 93.5% at 1 year, 76.2% at 5 years, and 70.1% at 10 years. These figures confirm that radiosurgical ablation prevents local regrowth in a clear majority of treated individuals. Progression-free survival rates followed a similarly favorable trajectory, recorded at 92.4% at 1 year, 73.6% at 5 years, and 64.8% at 10 years. Furthermore, overall survival remained remarkably robust throughout the observation period. Actuarial overall survival was 98.2% at 1 year, 93.6% at 5 years, and 85.2% at 10 years. These long-term metrics illustrate that stereotactic radiosurgery offers sustained disease stabilization without compromising overall survival. Consequently, for patients harboring surgically unresectable or recurrent tumor remnants, radiosurgical delivery provides an effective alternative to repeated high-risk craniotomies.

Impact of Solid-Cystic Phenotypes on Radiosurgical Success

Tumor morphology emerged as a pivotal determinant influencing radiosurgical response and overall treatment success. Craniopharyngiomas frequently manifest as solid, cystic, or mixed solid-cystic phenotypes. Notably, the IRRF analysis revealed that mixed solid-cystic lesions experienced significantly poorer local control compared to non-mixed variants. Log-rank testing demonstrated a statistically significant difference in control rates between these morphological groups. Furthermore, multivariable Cox regression confirmed that non-mixed tumor morphology independently predicted superior local control with a hazard ratio of 0.53. Cystic components often expand unpredictably due to ongoing fluid secretion, causing mechanical displacement and altered dosimetry. Consequently, cystic recurrence may necessitate supplementary interventional strategies, such as stereotactic intracystic aspiration, bleomycin instillation, or catheter-reservoir placement. Therefore, clinicians must carefully stratify craniopharyngioma morphology when planning radiation delivery and establishing surveillance intervals.

Preservation of Visual Acuity, Endocrine Integrity, and Safety

Preserving neurocognitive, visual, and endocrine functions remains paramount when treating sellar tumors. The IRRF study documented outstanding functional safety profiles following radiosurgical intervention. Visual field assessments demonstrated improvement in 10% of patients, stability in 86%, and deterioration in only 4%. Visual acuity improved in 6%, remained unchanged in 91%, and deteriorated in 3%. These figures highlight excellent optic pathway preservation when adhering to stringent dose-volume constraints. Similarly, endocrinologic outcomes remained exceptionally stable over time. Actuarial freedom from endocrine deterioration reached 96.7% at 10 years post-treatment. Diabetes insipidus symptoms improved in 6.3% of patients and worsened in only 0.5%. New or aggravated anterior pituitary dysfunction developed in merely 2.6% of the cohort. Thus, stereotactic radiosurgery demonstrates minimal risk of secondary hypopituitarism or radiation-induced optic neuropathy, underscoring its favorable therapeutic ratio.

Clinical Implications and Multidisciplinary Decision-Making

These multi-institutional findings have immediate relevance for neuro-oncology multidisciplinary teams. Historically, surgeons frequently pursued radical resections despite heightened risks of devastating morbidity. However, these data confirm that intentional subtotal decompression followed by stereotactic radiosurgery delivers excellent long-term local control. This combined strategy successfully safeguards patient quality of life. Clinicians must establish collaborative workflows involving neurosurgeons, radiation oncologists, and endocrinologists. Regular neuroimaging and visual field assessments should occur every 3 to 6 months during early surveillance. Furthermore, patients presenting with large cystic components require tailored combined modalities, potentially integrating stereotactic cyst drainage before radiation delivery. By tailoring radiosurgical parameters and considering tumor phenotype, clinicians can maximize durable tumor control while preserving neurological and hormonal function.

Frequently Asked Questions

What is the primary role of stereotactic radiosurgery in managing craniopharyngioma?

Stereotactic radiosurgery serves as an effective adjuvant or salvage therapy for residual, unresectable, or recurrent craniopharyngiomas. It delivers precise, high-dose conformal radiation while sparing critical adjacent structures such as the optic chiasm and hypothalamus, thereby achieving durable local control with minimal functional morbidity.

Why do mixed solid-cystic tumors exhibit lower local control rates?

Mixed solid-cystic craniopharyngiomas often exhibit dynamic fluid accumulation within the cyst cavity, leading to mechanical expansion and unpredictable geometrical changes. These shifts alter stereotactic dosimetry, reduce uniform radiation distribution, and frequently require supplementary interventions such as stereotactic aspiration or intracystic therapies.

How does radiosurgery affect neuroendocrine and visual pathways over time?

Radiosurgery demonstrates an excellent long-term safety profile. The IRRF study reported that 96.7% of patients remained free from endocrine deterioration at 10 years. Furthermore, visual acuity and visual fields remained stable or improved in more than 96% of evaluated patients.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Healthcare professionals should rely on clinical judgment and refer to the latest local and national guidelines for clinical practice.

References

1. Niranjan A et al. Stereotactic radiosurgery offers long-term tumor control for craniopharyngioma: a multi-institutional analysis of clinical and imaging outcomes from the International Radiosurgery Research Foundation (IRRF). J Neurooncol. 2026 Aug 03. doi: 10.1007/s11060-026-05718-w. PMID: 42545447.
2. Yoo HJ, Ham CH, Roh H, et al. Radiosurgery versus radiation therapy for long term local control rate of craniopharyngioma: a meta-analysis. Neurosurg Rev. 2025;48(1):93. doi:10.1007/s10143-025-03238-1.
3. Lee BM, Cho J, Kim DS, et al. Differences in Treatment Outcomes Depending on the Adjuvant Treatment Modality in Craniopharyngioma. Yonsei Med J. 2025;66(3):141-150. doi:10.3349/ymj.2023.0566.